
Outset Medical (OM) Stock Forecast & Price Target
Outset Medical (OM) Analyst Ratings
Bulls say
Outset Medical Inc has demonstrated a robust demand for its innovative dialysis technology, with management confirming a solid and expanding order pipeline that reflects continued growth from Q4 to Q1. Notably, the company is on track to achieve EBITDA positivity at sales levels of less than $200 million by 2028, bolstered by its ongoing revenue generation from Tablo consoles and consumables. Furthermore, the assurance of sufficient funding to reach profitability enhances the positive outlook for the company's future financial performance.
Bears say
Outset Medical Inc. faces significant challenges due to its reliance on a single product, the Tablo system, which necessitates continuous innovation to remain competitive. The company has not achieved profitability and may not do so for an extended period, raising concerns about its financial sustainability. Additionally, the commercial strategy is heavily dependent on the successful adoption of Tablo in acute care settings, which may not materialize as projected, further straining revenue growth prospects.
This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.
Outset Medical (OM) Analyst Forecast & Price Prediction
Start investing in Outset Medical (OM)
Order type
Buy in
Order amount
Est. shares
0 shares